scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Francesca Buontempo | Q57070544 |
Camilla Evangelisti | Q57233682 | ||
P2093 | author name string | James A McCubrey | |
Alberto M Martelli | |||
Milena Fini | |||
Daniela Bressanin | |||
Francesca Chiarini | |||
Alessandra Cappellini | |||
P2860 | cites work | The Hallmarks of Cancer | Q221226 |
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery | Q24302549 | ||
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive | Q24306328 | ||
Mechanism of activation of protein kinase B by insulin and IGF-1 | Q24309528 | ||
The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation | Q24315972 | ||
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia | Q24596097 | ||
A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin | Q24599904 | ||
Targeting mTOR for the treatment of AML. New agents and new directions | Q24617223 | ||
PHLiPPing the switch on Akt and protein kinase C signaling | Q24625894 | ||
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy | Q24632296 | ||
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1 | Q24645183 | ||
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy | Q24651380 | ||
AKT/PKB signaling: navigating downstream | Q24657857 | ||
Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms | Q24658292 | ||
Diversity of human leukemia xenograft mouse models: implications for disease biology | Q26827102 | ||
The phosphoinositide 3-kinase pathway | Q27860738 | ||
Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit | Q28115545 | ||
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice | Q28131777 | ||
Ribosomal S6 kinase 2 inhibition by a potent C-terminal repressor domain is relieved by mitogen-activated protein-extracellular signal-regulated kinase kinase-regulated phosphorylation | Q28139589 | ||
FLT-3: a new focus in the understanding of acute leukemia | Q28240705 | ||
Oral treatment for multiple sclerosis | Q28250892 | ||
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors | Q36076643 | ||
XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. | Q36322684 | ||
Treatment of acute lymphoblastic leukemia | Q36366185 | ||
Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells | Q36402419 | ||
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells | Q36508937 | ||
mTOR, translation initiation and cancer | Q36623679 | ||
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2 | Q36710799 | ||
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells | Q36835733 | ||
Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. | Q36894740 | ||
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas | Q36958575 | ||
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma | Q37003323 | ||
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia | Q37009642 | ||
Akt-dependent and -independent mechanisms of mTOR regulation in cancer | Q37114404 | ||
Protein phosphatase 2A regulatory subunits and cancer. | Q37202956 | ||
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 | ||
The role of PTEN signaling perturbations in cancer and in targeted therapy | Q37270446 | ||
Drug discovery approaches targeting the PI3K/Akt pathway in cancer | Q37270455 | ||
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q37303838 | ||
Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles | Q37308049 | ||
PI3K/Akt: getting it right matters | Q37310202 | ||
Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing | Q37328355 | ||
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia | Q37331742 | ||
Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside | Q37352422 | ||
Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. | Q37376549 | ||
Emerging treatments in acute lymphoblastic leukemia | Q37387692 | ||
Fine tuning the immune response with PI3K. | Q37416276 | ||
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies | Q37432231 | ||
Noxa: at the tip of the balance between life and death. | Q37566236 | ||
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways | Q37623440 | ||
Targeting mTOR globally in cancer: thinking beyond rapamycin | Q37630203 | ||
Essential roles of VLA-4 in the hematopoietic system | Q37721247 | ||
The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. | Q37732880 | ||
PI3K as a target for therapy in haematological malignancies | Q37762201 | ||
Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment | Q37766351 | ||
Autophagy is a therapeutic target in anticancer drug resistance. | Q37773489 | ||
Targeted cancer therapy: what if the driver is just a messenger? | Q40657287 | ||
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. | Q40887186 | ||
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway | Q41841005 | ||
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis | Q42193246 | ||
TP53 and MTOR crosstalk to regulate cellular senescence | Q42356990 | ||
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia | Q42381521 | ||
Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation | Q42448479 | ||
Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients | Q42500588 | ||
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function | Q42592644 | ||
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling | Q42634732 | ||
Targeting TOR dependence in cancer | Q42713384 | ||
Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex | Q42730946 | ||
Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling | Q42737210 | ||
P3Kα: a driver of tumor metastasis? | Q42751622 | ||
mTOR pathway activation in age-related retinal disease | Q42762402 | ||
Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. | Q42794694 | ||
Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. | Q42810841 | ||
Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. | Q42820035 | ||
NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols | Q42878950 | ||
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor | Q43117051 | ||
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. | Q43247819 | ||
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. | Q43515530 | ||
Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells | Q43599325 | ||
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins | Q44117862 | ||
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia | Q44279382 | ||
Survival of acute myeloid leukemia cells requires PI3 kinase activation | Q44408364 | ||
Genetic variegation of clonal architecture and propagating cells in leukaemia | Q44426152 | ||
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable | Q44443469 | ||
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia | Q44536202 | ||
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin | Q44605109 | ||
Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7 | Q44648992 | ||
Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. | Q44902570 | ||
Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma | Q79765253 | ||
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies | Q80209074 | ||
CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL | Q81100931 | ||
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells | Q81394615 | ||
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia | Q83030425 | ||
A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 | Q83350735 | ||
Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia | Q83557743 | ||
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry | Q83977171 | ||
Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function | Q28254826 | ||
Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction | Q28378871 | ||
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) | Q28640016 | ||
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining | Q29614339 | ||
Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells | Q29616552 | ||
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo | Q29619355 | ||
Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase | Q30160114 | ||
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. | Q30177048 | ||
Association of phosphatidylinositol 3-kinase with SHC in chronic myelogeneous leukemia cells. | Q30193531 | ||
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies | Q33379469 | ||
Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia | Q33493174 | ||
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor | Q33597663 | ||
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice | Q33608760 | ||
Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). | Q33645760 | ||
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. | Q33677433 | ||
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody | Q33707416 | ||
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction | Q33722630 | ||
Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation | Q33732463 | ||
Acute myeloid leukemia | Q33741270 | ||
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance | Q33755338 | ||
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. | Q34024558 | ||
Arsenic trioxide - An old drug rediscovered | Q34054167 | ||
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia | Q34164289 | ||
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway | Q34173253 | ||
The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells | Q34173746 | ||
INPP4B: the new kid on the PI3K block | Q34177821 | ||
Functional proteomic profiling of AML predicts response and survival | Q34184598 | ||
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control | Q34202681 | ||
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia | Q34213539 | ||
Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. | Q34387833 | ||
Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling | Q34391120 | ||
Suppression of leukemia development caused by PTEN loss | Q34533833 | ||
Personalized Medicine: Marking a New Epoch in Cancer Patient Management | Q37778667 | ||
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies | Q37779489 | ||
Modern therapy of acute lymphoblastic leukemia | Q37827276 | ||
Leukemia stem cells and microenvironment: biology and therapeutic targeting | Q37827279 | ||
Therapeutic advances in acute myeloid leukemia | Q37827282 | ||
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. | Q37836931 | ||
The biological and therapeutic relevance of mRNA translation in cancer | Q37848652 | ||
Targeting translation dependence in cancer | Q37850227 | ||
The cancer stem cell: premises, promises and challenges | Q37851011 | ||
Gene expression profiling in MDS and AML: potential and future avenues. | Q37858877 | ||
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives | Q37862648 | ||
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
Autophagy as a target for anticancer therapy | Q37876679 | ||
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells | Q37886012 | ||
Cytokines and microRNA in pediatric B-acute lymphoblastic leukemia | Q37901917 | ||
Notch in T-ALL: new players in a complex disease. | Q37903126 | ||
The clinical and therapeutic implications of cancer stem cell biology | Q37909375 | ||
Cancer stem cells in tumor heterogeneity. | Q37933902 | ||
AMPK and mTOR in cellular energy homeostasis and drug targets | Q37948152 | ||
The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. | Q37953891 | ||
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications | Q37976243 | ||
Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase | Q38338053 | ||
The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. | Q39404545 | ||
Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. | Q39414084 | ||
Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. | Q39441263 | ||
Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation | Q39497826 | ||
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity | Q39507948 | ||
Levels of p27 sensitize to dual PI3K/mTOR inhibition | Q39529578 | ||
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. | Q39590044 | ||
Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor | Q39591379 | ||
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide | Q39593159 | ||
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance | Q39596672 | ||
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors | Q39600915 | ||
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia | Q39643259 | ||
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 | ||
Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. | Q39653276 | ||
WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant | Q39696876 | ||
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor | Q39718159 | ||
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth | Q34582832 | ||
The two TORCs and Akt. | Q34617423 | ||
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study | Q34627586 | ||
Normalizing a hyperactive mTOR initiates muscle growth during obesity | Q34852371 | ||
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia | Q34923824 | ||
PI3K and mTOR inhibitors: a new generation of targeted anticancer agents | Q34939865 | ||
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging | Q34966603 | ||
Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias | Q34973772 | ||
PKB binding proteins. Getting in on the Akt. | Q34990565 | ||
Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group | Q34992080 | ||
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse | Q35102275 | ||
The role of SHIP in cytokine-induced signaling | Q35106192 | ||
Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. | Q35144582 | ||
Role of Pten in leukemia stem cells | Q35169570 | ||
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling | Q35208383 | ||
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis | Q35217174 | ||
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients | Q35316765 | ||
High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse | Q35528643 | ||
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs | Q35640098 | ||
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | Q35640228 | ||
Elevated PI3K signaling drives multiple breast cancer subtypes | Q35640263 | ||
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. | Q35640320 | ||
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. | Q35651744 | ||
Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. | Q35664310 | ||
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 | ||
Targets and mechanisms for the regulation of translation in malignant transformation | Q35750114 | ||
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | Q35751042 | ||
Will PI3K pathway inhibitors be effective as single agents in patients with cancer? | Q35764392 | ||
Advances in protein kinase B signalling: AKTion on multiple fronts | Q35766370 | ||
mTOR regulates cell survival after etoposide treatment in primary AML cells | Q35848196 | ||
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL | Q35850028 | ||
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia | Q35945171 | ||
Concise review: Emerging concepts in clinical targeting of cancer stem cells | Q35971159 | ||
Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry | Q45029000 | ||
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
Antileukemic activity of rapamycin in acute myeloid leukemia. | Q45154681 | ||
PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways | Q45259661 | ||
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Q46003222 | ||
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. | Q46047974 | ||
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells | Q46375225 | ||
Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells | Q46477311 | ||
Leukemia stem cells | Q46509360 | ||
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. | Q46544691 | ||
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. | Q46544703 | ||
Targeting PI3K/mTOR signaling in cancer | Q46617891 | ||
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. | Q47259599 | ||
Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. | Q47268104 | ||
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia | Q47290417 | ||
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype | Q48059777 | ||
Nutrient sensing in the mTOR/S6K1 signalling pathway | Q48235664 | ||
The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. | Q50510141 | ||
Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. | Q50649768 | ||
Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. | Q51008910 | ||
Stem cell gene expression programs influence clinical outcome in human leukemia. | Q51856192 | ||
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. | Q51890946 | ||
Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. | Q51900663 | ||
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. | Q52576345 | ||
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. | Q52906689 | ||
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. | Q53275436 | ||
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. | Q53334759 | ||
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. | Q53526869 | ||
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. | Q54635631 | ||
Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma. | Q55239327 | ||
Acute lymphoblastic leukaemia | Q56722375 | ||
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation | Q56995267 | ||
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion | Q56995355 | ||
Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia | Q57220263 | ||
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF- B and JNK/AP-1 pathways | Q57425916 | ||
GAB2 is a novel target of 11q amplification in AML/MDS | Q58957431 | ||
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention | Q59067116 | ||
Tumor growth need not be driven by rare cancer stem cells | Q59606871 | ||
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice | Q60171380 | ||
Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia | Q61774820 | ||
Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations | Q62658217 | ||
Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome | Q73701961 | ||
Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia | Q79143621 | ||
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de | Q79527735 | ||
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells | Q39746076 | ||
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. | Q39790449 | ||
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. | Q39832054 | ||
RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia | Q39861488 | ||
SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. | Q39921977 | ||
AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. | Q39932311 | ||
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability | Q39933367 | ||
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor | Q39941278 | ||
A critical role for Lyn in acute myeloid leukemia. | Q40040911 | ||
Eradicating cancer cells: struggle with a chameleon | Q40047489 | ||
Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. | Q40054340 | ||
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway | Q40117414 | ||
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. | Q40118489 | ||
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia | Q40158237 | ||
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance | Q40225720 | ||
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma | Q40280414 | ||
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein | Q40351786 | ||
Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. | Q40377835 | ||
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias | Q40382560 | ||
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia | Q40400934 | ||
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells | Q40435523 | ||
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells | Q40488705 | ||
Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. | Q40501536 | ||
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species | Q40503994 | ||
Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. | Q40538322 | ||
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells | Q40548220 | ||
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias | Q40615155 | ||
P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute leukemia | Q976388 |
mechanism of action | Q3271540 | ||
phosphoinositide-3 kinase inhibitor | Q7187512 | ||
enzyme | Q8047 | ||
leukemia | Q29496 | ||
Serine/threonine-protein kinase TOR | Q24723029 | ||
sirolimus | Q32089 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | 371-394 | |
P577 | publication date | 2012-04-01 | |
P1433 | published in | Oncotarget | Q1573155 |
P1476 | title | Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment | |
P478 | volume | 3 |
Q36926129 | A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
Q30458968 | Activation of GABA(B) receptors inhibits protein kinase B/glycogen synthase kinase 3 signaling |
Q27686983 | Advances in targeting signal transduction pathways |
Q37729067 | Application and interpretation of current autophagy inhibitors and activators |
Q36270307 | Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia |
Q39158015 | Cell death sensitization of leukemia cells by opioid receptor activation |
Q35832986 | Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells |
Q36544778 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia |
Q30557008 | Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer |
Q37012626 | Combined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis |
Q37704928 | Cyclic ADP-Ribose and NAADP in Vascular Regulation and Diseases |
Q37377906 | Cytoplasmic localization of wild-type survivin is associated with constitutive activation of the PI3K/Akt signaling pathway and represents a favorable prognostic factor in patients with acute myeloid leukemia |
Q39221970 | DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia |
Q34103963 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention |
Q38187149 | Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. |
Q33632845 | Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy |
Q28394310 | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies |
Q36777229 | ER stress: Autophagy induction, inhibition and selection. |
Q36556350 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine |
Q52649710 | Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines. |
Q34786480 | Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia |
Q34848294 | Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial |
Q42541266 | Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients |
Q37065337 | Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas |
Q37588340 | Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion |
Q94547358 | Fasting to enhance Cancer treatment in models: the next steps |
Q27013811 | GSK-3 as potential target for therapeutic intervention in cancer |
Q36339232 | Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels |
Q42505783 | Immunosuppressants in cancer prevention and therapy |
Q41965978 | Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress |
Q35071010 | Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. |
Q53314331 | Inhibition of Ras-mediated signaling pathways in CML stem cells. |
Q36990482 | Integration of Different "-omics" Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells |
Q89599313 | Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? |
Q36292001 | Koschei the immortal and anti-aging drugs |
Q30977659 | Lack of BRAF-V600E Mutation in Papillary Tumor of the Pineal Region |
Q57292823 | MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells |
Q37649646 | MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia |
Q38038993 | Mechanisms of reproductive aging in the females |
Q39265746 | Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. |
Q28081657 | Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment |
Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
Q38500371 | Novel approaches to pediatric leukemia treatment |
Q90721907 | Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia |
Q26801538 | PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application |
Q37132224 | Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells |
Q37046021 | Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome |
Q39004520 | Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. |
Q38497014 | Proteotoxicity and cardiac dysfunction |
Q37228766 | Rapamycin extends life- and health span because it slows aging |
Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
Q36926098 | Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes |
Q37011768 | Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors |
Q35729047 | Sann-Joong-Kuey-Jian-Tang induces autophagy in HepG2 cells via regulation of the phosphoinositide-3 kinase/Akt/mammalian target of rapamycin and p38 mitogen-activated protein kinase pathways |
Q39067602 | Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. |
Q35781507 | Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer |
Q36989223 | Targeted drug discovery for pediatric leukemia |
Q38364871 | Targeting PI3K/AKT/mTOR network for treatment of leukemia. |
Q38208314 | Targeting PI3K/Akt/mTOR Signaling in Cancer |
Q39109921 | Targeting acute myeloid leukemia stem cell signaling by natural products. |
Q64118363 | Targeting mTOR in Acute Lymphoblastic Leukemia |
Q38113583 | Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia |
Q39119297 | Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. |
Q56378380 | Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update |
Q33952803 | Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia |
Search more.